Garcia Joseph H, Morshed Ramin A, Chung Jason, Millares Chavez Miguel A, Sudhakar Vivek, Saggi Satvir, Avalos Lauro N, Gallagher Aaron, Young Jacob S, Daras Mariza, McDermott Michael W, Garcia Paul A, Chang Edward F, Aghi Manish K
1Department of Neurological Surgery and.
2Department of Neurology, University of California, San Francisco, California.
J Neurosurg. 2022 Apr 29;138(1):19-26. doi: 10.3171/2022.3.JNS212285. Print 2023 Jan 1.
Epileptic seizures are a common and potentially devastating complication of metastatic brain tumors. Although tumor-related seizures have been described in previous case series, most studies have focused on primary brain tumors and have not differentiated between different types of cerebral metastases. The authors analyzed a large surgical cohort of patients with brain metastases to examine risk factors associated with preoperative and postoperative seizures and to better understand the seizure risk factors of metastatic brain tumors.
Patients who underwent resection of a brain metastasis at the University of California, San Francisco (UCSF), were retrospectively reviewed. Patients included in the study were ≥ 18 years of age, required resection of a brain metastasis, and were treated at UCSF. Primary cancers included melanoma, non-small cell lung adenocarcinoma, breast adenocarcinoma, colorectal adenocarcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, renal cell carcinoma, urothelial carcinoma, ovarian carcinoma, cervical squamous cell carcinoma, and endometrial adenocarcinoma. Patients were evaluated for primary cancer type and seizure occurrence, as well as need for use of antiepileptic drugs preoperatively, at time of discharge, and at 6 months postoperatively. Additionally, Engel classification scores were assigned to those patients who initially presented with seizures preoperatively. Univariate and multivariate regression analyses were used to assess the association of tumor type with preoperative seizures.
Data were retrospectively analyzed for 348 consecutive patients who underwent surgical treatment of brain metastases between 1998 and 2019. The cohort had a mean age of 60 years at the time of surgery and was 59% female. The mean and median follow-up durations after the date of surgery for the cohort were 22 months and 10.8 months, respectively. In univariate analysis, frontal lobe location (p = 0.05), melanoma (p = 0.02), KRAS mutation in lung carcinoma (p = 0.04), intratumoral hemorrhage (p = 0.04), and prior radiotherapy (p = 0.04) were associated with seizure presentation. Postoperative checkpoint inhibitor use (p = 0.002), prior radiotherapy (p = 0.05), older age (p = 0.002), distant CNS progression (p = 0.004), and parietal lobe tumor location (p = 0.002) were associated with seizures at 6 months postoperatively. The final multivariate model confirmed the independent effects of tumor location in the frontal lobe and presence of intratumoral hemorrhage as predictors of preoperative seizures, and checkpoint inhibitor use and parietal lobe location were identified as significant predictors of seizures at 6 months postoperatively.
Within this surgical cohort of patients with brain metastases, seizures were seen in almost a quarter of patients preoperatively. Frontal lobe metastases and hemorrhagic tumors were associated with higher risk of preoperative seizures, whereas checkpoint inhibitor use and parietal lobe tumors appeared to be associated with seizures at 6 months postoperatively. Future research should focus on the effect of metastatic lesion-targeting therapeutic interventions on seizure control in these patients.
癫痫发作是转移性脑肿瘤常见且可能具有毁灭性的并发症。尽管在先前的病例系列中已描述过与肿瘤相关的癫痫发作,但大多数研究集中于原发性脑肿瘤,且未区分不同类型的脑转移瘤。作者分析了一大组接受手术治疗的脑转移瘤患者,以研究与术前和术后癫痫发作相关的危险因素,并更好地了解转移性脑肿瘤的癫痫发作危险因素。
对在加利福尼亚大学旧金山分校(UCSF)接受脑转移瘤切除术的患者进行回顾性研究。纳入研究的患者年龄≥18岁,需要切除脑转移瘤,并在UCSF接受治疗。原发性癌症包括黑色素瘤、非小细胞肺腺癌、乳腺腺癌、结直肠腺癌、食管腺癌、胃腺癌、肾细胞癌、尿路上皮癌、卵巢癌、宫颈鳞状细胞癌和子宫内膜腺癌。评估患者的原发性癌症类型、癫痫发作情况,以及术前、出院时和术后6个月使用抗癫痫药物的必要性。此外,对术前最初出现癫痫发作的患者进行Engel分类评分。采用单因素和多因素回归分析评估肿瘤类型与术前癫痫发作的相关性。
对1998年至2019年间连续348例接受脑转移瘤手术治疗的患者进行回顾性分析。该队列患者手术时的平均年龄为60岁,女性占59%。该队列手术后的平均随访时间和中位随访时间分别为22个月和10.8个月。在单因素分析中,额叶位置(p = 0.05)、黑色素瘤(p = 0.02)、肺癌中的KRAS突变(p = 0.04)、瘤内出血(p = 0.04)和既往放疗(p = 0.04)与癫痫发作表现相关。术后使用检查点抑制剂(p = 0.002)、既往放疗(p = 0.05)、年龄较大(p = 0.002)、远处中枢神经系统进展(p = 0.004)和顶叶肿瘤位置(p = 0.002)与术后6个月的癫痫发作相关。最终的多因素模型证实额叶肿瘤位置和瘤内出血的存在作为术前癫痫发作预测因素的独立作用,并且使用检查点抑制剂和顶叶位置被确定为术后6个月癫痫发作的重要预测因素。
在这个接受手术治疗的脑转移瘤患者队列中,近四分之一的患者术前出现癫痫发作。额叶转移瘤和出血性肿瘤与术前癫痫发作的较高风险相关,而使用检查点抑制剂和顶叶肿瘤似乎与术后6个月的癫痫发作相关。未来的研究应关注针对转移性病变的治疗干预对这些患者癫痫控制的影响。